(Q63405357)
Statements
Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma (English)
0 references
2 February 2018
0 references
30 September 2020
0 references
45
0 references
21 year
0 references